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Background A third of people with juvenile myoclonic epilepsy (JME) are drug-resistant. Three-quarters have a seizure relapse
when attempting to withdraw anti-seizure medication (ASM) after achieving seizure-freedom. It is currently impossible to
predict who is likely to become drug-resistant and safely withdraw treatment. We aimed to identify predictors of drug
resistance and seizure recurrence to allow for individualised prediction of treatment outcomes in people with JME.
Methods We performed an individual participant data (IPD) meta-analysis based on a systematic search in EMBASE
and PubMed – last updated on March 11, 2021 – including prospective and retrospective observational studies
reporting on treatment outcomes of people diagnosed with JME and available seizure outcome data after a
minimum one-year follow-up. We invited authors to share standardised IPD to identify predictors of drug
resistance using multivariable logistic regression. We excluded pseudo-resistant individuals. A subset who
attempted to withdraw ASM was included in a multivariable proportional hazards analysis on seizure recurrence
after ASM withdrawal. The study was registered at the Open Science Framework (OSF; https://osf.io/b9zjc/).
Findings Our search yielded 1641 articles; 53 were eligible, of which the authors of 24 studies agreed to collaborate by
sharing IPD. Using data from 2518 people with JME, we found nine independent predictors of drug resistance: three
seizure types, psychiatric comorbidities, catamenial epilepsy, epileptiform focality, ethnicity, history of CAE, family
history of epilepsy, status epilepticus, and febrile seizures. Internal-external cross-validation of our multivariable
model showed an area under the receiver operating characteristic curve of 0⋅70 (95%CI 0⋅68–0⋅72). Recurrence of
seizures after ASM withdrawal (n = 368) was predicted by an earlier age at the start of withdrawal, shorter
seizure-free interval and more currently used ASMs, resulting in an average internal-external cross-validation
concordance-statistic of 0⋅70 (95%CI 0⋅68–0⋅73).
Interpretation We were able to predict and validate clinically relevant personalised treatment outcomes for people
with JME. Individualised predictions are accessible as nomograms and web-based tools.
Funding MING fonds.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Keywords: Juvenile myoclonic epilepsy; Prediction model; Refractory epilepsy; Drug resistance; Medication
withdrawal; Remission; Multivariable prediction; JME; Seizure recurrence; Meta-analysis; Individual participant data
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Research in context
Evidence before this study
A third of people with JME are drug-resistant, and threequarters of individuals with JME who attempted to withdraw
treatment after becoming seizure-free experienced a seizure
recurrence. We last performed a systematic literature search in
PubMed and Embase on 11 March 2021 by searching for
‘juvenile myoclonic epilepsy’ and ‘treatment outcome’ and
various synonyms. We found no sufﬁciently powered
multivariable analyses that assessed potential predictors of
drug-resistant JME or predictors of seizure recurrence after
ASM withdrawal.
Added value of this study
This individual participant data (IPD) meta-analysis (n = 2518)
identiﬁed nine independent predictors of drug-resistant JME,
seven previously reported, and two novel: ethnicity and family

history of epilepsy. We found three predictors of seizure
recurrence after treatment withdrawal. The strongest
predictor for post-withdrawal seizure recurrence in JME –
earlier age at the start of withdrawal – had an inverse
direction of effect compared to other epilepsy types. We used
these variables to create prediction models of drug-resistant
JME and of seizure recurrence. Internal-external crossvalidation showed robust predictive performance of our
models.
Implications of all the available evidence
We created and validated prediction models, available as
nomograms and web-based tools, to improve and personalise
JME treatment. We expect that the models will aid in
improving and personalising the treatment and counselling of
people with JME.

Introduction

Methods

Juvenile myoclonic epilepsy (JME) is the most common idiopathic and presumed genetic generalised
epilepsy syndrome, affecting 5–10% of all people
with epilepsy.1 Response to anti-seizure medication
(ASM) is often assumed to be good,2,3 but we
recently reported that a third of all people with JME
are drug-resistant.4 People with JME are widely
believed to require lifelong treatment.5,6 After a
period of seizure freedom, however, around a quarter
of those who withdraw treatment may remain
seizure-free.4
Predicting who is likely to become drug-resistant
and who could safely withdraw ASM treatment after
a certain period of sustained seizure-freedom, has
clinical beneﬁts. Drug withdrawal improves quality of
life by avoiding the adverse effects of potentially unnecessary treatment.7,8 We previously identiﬁed 43
reports providing treatment outcomes in cohorts of
people with JME.4 We found six prognostic risk factors for drug resistance. Some of these risk factors are
collinear, and it is unknown which have independent
predictive value. Recent published multivariable prediction models of drug resistance had intrinsic limitations due to relatively small and heterogeneous
cohorts, including different types of generalised epilepsy.9,10 There are currently no known risk factors for
seizure relapse after ASM withdrawal in JME, other
than those previously identiﬁed in the broader epilepsy population.11
We aimed to identify independent predictors
of drug resistance and post-withdrawal relapse risk
based on individual participant data (IPD) from
previously published study cohorts. We developed
and validated predictive tools to calculate these risks.

Search strategy and selection criteria

www.thelancet.com Vol 53 November, 2022

We performed a meta-analysis of individual participant
data according to a pre-registered protocol (https://osf.
io/b9zjc/). The methods and reporting are consistent
with the PRISMA-IPD12 and TRIPOD statements.13 We
systematically searched PubMed and EMBASE for articles published in English, Dutch, German, Spanish or
French describing treatment outcomes in observational
cohorts of people with JME, with no date restrictions.
The literature search was last updated by RS on March
11, 2021, using the same search terms and study-level
inclusion and exclusion criteria as in a previously published meta-analysis4: we included retrospective and
prospective studies reporting on treatment outcomes of
people with a diagnosis of JME. As individuals were
diagnosed before the proposed consensus criteria,5 our
diagnoses were primarily made according to descriptive
criteria. JME is a distinctive syndrome characterised by
juvenile-onset myoclonic seizures and generalised tonicclonic seizures (GTCS), usually occurring after
wakening and evoked by sleep deprivation, alcohol
consumption, and especially a combination of irregular
spike and wave discharges in the EEG.2 We excluded
articles exclusively reporting on people with drugresistant JME or in remission. We excluded drug trials
as these could be biased towards people with drugresistant JME. We used three individual-level inclusion
criteria: (1) clinical diagnosis of JME, regardless of the
diagnostic criteria used by the study,5 (2) at least one
year of follow-up, and (3) available information
regarding seizure outcome, with ASM use. People with
pseudo-resistant epilepsy were excluded, i.e. seizures
due to non-compliance, inadequate treatment or inadequate lifestyle regulation.14 People who had attempted to
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withdraw ASM after a period of seizure freedom were
included in an analysis to assess predictors of seizure
relapse after ASM withdrawal. We found one additional
article by cross-referencing.
We invited the corresponding authors of all potentially eligible studies to collaborate by sharing IPD. If we
received no reply, we sent two reminders 4–6 weeks
apart, and when possible, we contacted additional authors of the same study. We searched ResearchGate, the
International League Against Epilepsy (ILAE) website,
other publications by the same authors and performed a
manual internet search for alternative contact details.
Authors who agreed to collaborate were asked to
provide treatment outcome data and potential predictors
by ﬁlling in a standardised data entry sheet containing
41 variables (Supplementary Table S1). Alternatively,
collaborators could send a datasheet in their format,
after which the coordinating investigator standardised
the data. Some collaborators could update their data
with additional variables or individuals not included in
their original publication. All datasets were manually
reviewed, and potential discrepancies were resolved by
discussion with the contributing author. We did not
include aggregate study data without IPD.
As in our previous meta-analysis, we used the
Newcastle–Ottawa quality assessment scale for cohort
studies to assess the methodological quality of all the
included studies.15 The scale ranges between 1 and 8,
where higher scores represent a higher quality and less
risk of bias.
Our study was a meta-analysis of de-identiﬁed individual data and did not require ethical approval or speciﬁc informed consent. Local research ethics
committees or other entities overseeing personal data
had approved the original studies. Where applicable
under local regulations, data sharing agreements were
signed before receiving individual data.

Outcome and predictor variables
We used a combination of outcome measures to deﬁne
drug resistance and seizure recurrence after ASM
withdrawal. For the primary analysis, we used the deﬁnition of drug-resistant epilepsy formulated by the ILAE,
taking each seizure type into account.16 This was deﬁned
as the failure of two or more adequate trials of welltolerated and appropriately chosen drug schedules. We
assessed whether people had not had seizures of any
type in the last one, two or ﬁve years of follow-up as
sensitivity analyses. Similarly, we speciﬁcally ascertained whether individuals were free of GTCS in the last
one, two or ﬁve years of follow-up, as these are the most
debilitating seizure type and are less likely to be
underreported.
We assessed seizure recurrence in a subset of people
who attempted to withdraw treatment after a period of
seizure freedom. Seizure recurrence was evaluated at

4

two and ﬁve years after initiation of ASM withdrawal.
Our primary analysis comprised recurrence of any
seizure after start of ASM withdrawal. We also specifically assessed GTCS recurrence.
We selected candidate predictors of drug resistance
and seizure recurrence based on our previous metaanalysis on refractory JME,4 our previous publication
on seizure recurrence in general cohorts of people with
epilepsy,11 and potential predictors identiﬁed by
included studies. We focused on readily available predictors in a routine clinical setting, excluding variables
such as advanced EEG processing data or functional
MRI biomarkers. Supplementary Table S1 provides an
overview of all outcome measures, predictors, and
deﬁnitions.

Data analysis
The supplementary methods provide a detailed overview of all analyses and statistical methods. In brief,
the proportion of drug-resistant JME was assessed
with random-effects meta-analysis and a metaregression of drug resistance by publication year.
Between-study heterogeneity was assessed using the I2
test, which is deﬁned as the percentage of total variation across studies that is due to heterogeneity rather
than chance.17 We created funnel plots and performed
Egger’s test to assess potential publication bias. Multiple imputations were used to deal with missing
data.18 Mixed-effects logistic regression analyses were
performed to evaluate potential risk factors for drug
resistance. First, all predictors with p < 0⋅2 were taken
forward to a multivariable model. The model was
reduced by backward selection of the least contributing
variables, based on the minimisation of the Akaike
information criterion. Internal-external cross-validation
was performed by leaving one cohort out of the
training dataset and validating the model on each
holdout cohort. The area under the receiver operating
curve (AUC) was computed by merging the predictions of each cross-validation iteration.19 As sensitivity analyses, we assessed the ability to predict
freedom of any seizure and freedom of GTCS in the
last one, two and ﬁve years of follow-up, based on the
same predictors.
Cox proportional hazards analyses were performed to
assess the time to seizure recurrence after start of ASM
withdrawal. Univariable predictors at p < 0⋅2 were used
for multivariable analyses, after which backward selection was performed to remove the least contributing
predictors. We performed an internal-external validation
by splitting the 18 cohorts with data on post-withdrawal
seizure recurrence into three datasets of 6 cohorts,
balanced on sample size. We trained the prediction
model on 12/18 cohorts and assessed the external predictive value of this model on the left-out 6 cohorts,
quantiﬁed with the concordance-statistic (C-statistic).20

www.thelancet.com Vol 53 November, 2022

Articles

Such non-random internal-external validations qualify
as external validations of the model.21,22
AUC and C-statistic values range between 0 and 1,
where a value of 0.5 represents no better prediction than
chance, and 1 represents perfect predictive performance. A value < 0.7 is generally considered poor, ≥0.7
is deemed acceptable, and ≥0.8 is considered excellent.23
All statistical analyses were performed in RStudio
Version 1.3.1093, using the packages: MICE, metafor,
glmer, rms, coxme, rsample, purrr, survminer, tidyverse, ggplot, and survAUC.

Nomogram and web-based risk assessment tool
To aid use in clinical practice, we converted our multivariable models to nomograms and web-based tools.
The nomograms are visual representations of the
mixed-effects logistic regression analysis on drug resistance and the Cox proportional hazards model on
seizure recurrence within 2 and 5 years. They come with
instructions to manually estimate clinical outcomes for
an individual. Similarly, we translated the models into
web-based tools where a user can ﬁll in predictors to
obtain the associated probability of a clinical outcome
for an individual.

Role of the funding source
The funder had no role in the study design, data
collection, data analysis, data interpretation, drafting of
the report or the decision to submit. RS, DA-T, WMO,
BPCK, FEJ, KPJB had full access to all the data. All
authors interpreted results, reviewed and critically
revised the article, and approved the ﬁnal version for
submission.

Results
We screened 1334 articles and identiﬁed 53 eligible
studies (Fig. 1). The authors of 24 of these studies were
able and willing to provide IPD. Four were prospective,
19 were retrospective, and one study had a mixed
retrospective
and
prospective
design
(see
Supplementary Table S2 for study characteristics).24–44
Eligible articles of which IPD was not included were
similar in design and proportion of drug resistance,
although some were markedly older and smaller
(Supplementary Table S3). Meta-regression incorporating non-included articles, did not show changes in
drug resistance by publication year (p = 0.44;
Supplementary Fig. S1). Based on the Newcastle Ottowa
assessment scale, the original publications’ quality
scores ranged between three to seven (mean 4⋅4;
Supplementary Table S4).
In total, 2518 individuals from 18 countries and
various ethnicities were included in the predictive analyses of drug resistance. Missing data before imputation
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ranged between 0% and 38% per variable (median
10⋅0%, IQR 0–19⋅4%). Among variables included in the
drug resistance analysis, three variables had missing
data between 25% and 40%; eight variables were
missing between 10% and 25%, ﬁve variables between
1% and 10%, and data was complete for seven variables
(Supplementary Fig. S2). Among variables included in
the seizure recurrence analysis, two variables were
missing between 25 and 45%, nine variables between
10% and 25%, ten variables between 1% and 10%, and
data were complete for ten variables (Supplementary
Fig. S3).
Follow-up duration ranged from one to 73 years
(median 8⋅0, IQR 4⋅0–16⋅0). Information on current
ASM treatment was available for 2365 people, of which
805 (34%) were on multiple ASMs, and 1560 (66%) were
on monotherapy (Supplementary Table S2). Among
those on monotherapy, valproate was most often used
(n = 826, 54%), followed by levetiracetam (n = 352, 23%)
and lamotrigine (n = 154, 10%). Amongst 2216 people
with known past ASM treatment, 661 (30%) were still
taking the ﬁrst prescribed medication, 727 (33%) had
used one, and 828 (37%) used two or more previous
ASMs (Supplementary Table S6). A subset of 368 people
with JME (15% of the total cohort) had attempted to
withdraw from ASM treatment at any time during
follow-up (median follow-up after the start of withdrawal: 4⋅0 years, IQR 1⋅5–9⋅0). Of these, 112 (30%)
were not using any ASM at the last follow-up.
Meta-analysis showed that 29% (95%CI 23–36%) of
people with JME were drug-resistant (Supplementary
Fig. S4), with signiﬁcant heterogeneity between studies
(I2 = 88%, p < 0⋅0001). Funnel plots (Supplementary
Fig. S4) and Egger’s test (p = 0.46) did not show evidence for publication bias. Amongst 388 drug-resistant
people with data on the most extended period of seizure
freedom, 250 (64%) had never been seizure-free for more
than 12 months, and 58 (15%) were never free of seizures
for more than 1 month at any point.
Univariable mixed-effects logistic regression analysis
identiﬁed 18 predictors of drug resistance at p < 0⋅2
(Table 1; distributions of drug resistance and seizure
recurrence concerning potential predictors are in
Supplementary Table S7 ), some of which were correlated (see Supplementary Table S7). After backward selection in multivariable analyses, we identiﬁed nine
variables with independent predictive values for drugresistant JME (Fig. 2, Supplemental Table S9): psychiatric comorbidities, three seizure types, focal epileptiform activity on EEG, catamenial epilepsy, status
epilepticus, history of febrile seizures, family history of
epilepsy, history of CAE progressing to JME, and
ethnicity. Associations were similar when restricted to
1163 cases with complete data (Supplementary
Table S10).
We performed internal-external cross-validation to
assess the external predictive value of the multivariable
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Hits from search string:
PubMed: 657
Embase: 984
Total: 1641

Duplicate studies: 307

Total arcles screened: 1334
Arcles not meeng
inclusion- and exclusion
criteria: 1267
Same cohort described in
mulple arcles: 15

Arcles found by crossreferencing: 1

Eligible arcles : 53
Authors not able or
willing to provide IPD: 13
No response: 8
Authors deceased or no
current contact details: 8

Included studies: 24
Subjects: 2518

Analysis of drug-resistant JME:
24 studies; 2518 subjects

Analysis of ASM withdrawal:
18 studies; 368 subjects

Fig. 1: Flowchart of search strategy and study selection.

model, which showed an AUC of 0⋅70 (95%CI
0⋅67–0⋅72). The AUC varied between 0⋅56 and 0⋅84 per
left-out cohort (median 0⋅70, IQR 0⋅66–0⋅76), with
smaller cohorts on both ends of the distribution
(Supplementary Table S11). A plot of predicted against
observed probabilities showed excellent calibration
(Fig. 2B).
As further sensitivity analyses, we assessed how well
we could predict freedom of any seizure and freedom of
GTCS in the last one, two and ﬁve years of follow-up.
We used the same predictors (see Supplementary
Table S12 for a correlation matrix of outcome measures), without considering the pre-treatment seizure
interval and the number and appropriateness of each
drug trial as in the drug resistance analyses. The AUC
for freedom of any seizure was 0⋅67 (95%CI 0⋅65–0⋅69)
for the last year, 0⋅63 (0⋅61–0⋅66) for two years, and 0⋅59
(0⋅56–0⋅61) for ﬁve years. The AUC of the prediction
model for freedom of GTCS, was 0⋅64 (0⋅61–0⋅67) for
the last year, 0⋅62 (0⋅59–0⋅64) for two years and 0⋅63
(0⋅60–0⋅66) for ﬁve years.
We performed survival analyses to assess the recurrence of seizures in people who attempted to withdraw
their ASM treatment (n = 368). These individuals were
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older and included more people of Asian ethnicity
compared to people who did not try to withdraw treatment but did not differ in other predictors of drug
resistance (Supplementary Table S13). Five years after
initiation of ASM withdrawal, 73% (95%CI 67–78%)
had experienced seizure relapses (Fig. 3). Slightly fewer
(69%, 95%CI 62–74%) had a seizure recurrence when
assessing only GTCS. Amongst 116 people restarting
treatment after a seizure recurrence and followed at
least two years after recurrence, 90 (78%) regained
freedom of any seizure for at least 12 months at the last
follow-up.
Univariable analyses showed ten predictors of
seizure recurrence at p < 0⋅2 (Table 1). Subsequent
multivariable analyses and backwards selection showed
three variables with independent predictive value
(Supplementary Table S14, Fig. 4): age at withdrawal,
the seizure-free interval before withdrawal and number
of ASM used at the start of reduction. Restricting analyses to 282 complete cases did not affect these associations (Supplementary Table S15). Internal-external
cross-validations by creating three splits of our data (6
cohorts per split) showed similar external predictive
performance for all three data splits (split 1: n = 119,
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Predictor

n (%) or median (IQR)

Association with drug
resistance
OR (95% CI)

Association with seizure
recurrence after ASM
withdrawal
p-value

HR (95% CI)

p-value

Gender
Male

978/2518 (38.8%)

0.84 (0.69–1.03)

Female

1540/2518 (61.2%)

Ref

0.088

Age at ﬁrst seizure (years)

15 (12–17)

0.96 (0.94–0.98)

0.00013

1.00 (0.97–1.02)

0.79

Age at last moment of follow-up (years)

29 (23–38)

1.01 (0.76–1.36)

0.922

0.38 (0.27–0.55)

<0.0001

Diagnostic delay (months)

1 (0–3)

1.13 (0.97–1.32)

0.12

0.99 (0.91–1.07)

0.82

–

0.92 (0.71–1.20)
Ref

0.55
–

Ethnicity
–

Ref

–

Caucasian

1263/2054 (61.5%)

Ref

Asian

510/2054 (24.8%)

0.46 (0.24–0.88)

0.022

0.91 (0.68–1.22)

0.53

Latin-American

85/2054 (4.2%)

1.31 (0.52–3.31)

0.56

0.94 (0.45–1.96)

0.87

Other or admixed

196/2054 (9.5%)

1.01 (0.32–3.20)

0.98

0.82 (0.26–2.61)

0.74

Yes

205/2331 (8.8%)

1.57 (1.14–2.17)

No

2126/2331 (91.2%)

Ref

Yes

68/2124 (3.2%)

2.29 (1.37–3.84)

No

2056/2124 (96.8%)

Ref

Yes

20/2011 (1%)

1.85 (0.76–4.49)

No

1991/2011 (99.0%)

Ref

History of febrile seizures
0.0065
–

0.69 (0.42–1.13)
Ref

0.14
–

Ever experienced status epilepticus
0.0018
–

1.22 (0.50–2.97)

0.66

Ref

Developmental delay
0.18
–

0.30
1.83 (0.58–5.74)

Neurological comorbidities
Yes

190/2518 (13.5%)

1.19 (0.84–1.68)

No

2328/2518 (86.5%)

Ref

0.33

1.07 (0.76–1.51)

–

0.68
–

Psychiatric comorbidities
Yes

416/2018 (20.6%)

2.27 (1.78–2.89)

<0.0001

1.28 (0.95–1.74)

No

1602/2018 (79.4%)

Ref

–

Ref

Yes

796/2318 (34.3%)

1.22 (0.99–1.51)

No

1522/2318 (65.7%)

Ref

–

Yes

2481/2518 (98.5%)

Ref

–

No

37/2518 (1.5%)

0.95 (0.41–2.18)

Yes

2322/2518 (92.2%)

1.42 (0.90–2.26)

No

196/2518 (7.8%)

Ref

Yes

788/2518 (31.3%)

2.93 (2.36–3.63)

<0.0001

1.48 (1.14–1.91)

No

1730/2518 (68.7%)

Ref

–

Ref

Yes

748/2518 (29.7%)

3.26 (2.64–4.02)

<0.0001

1.43 (1.10–1.86)

No

1770/2518 (70.3%)

Ref

–

Ref

0.11
–

Family history of epilepsy
0.068

0.90 (0.68–1.19)
Ref

0.45
–

Myoclonic seizures
0.37 (0.02–5.92)
0.90

Ref

0.49
–

Generalised tonic-clonic seizures (GTCS)
0.14
–

1.20 (0.71–2.03)
Ref

0.49
–

Absence seizures
0.0031
–

Three seizure types
0.0089
–

History of childhood absence epilepsy (CAE) progressing to JME
Yes

193/2247 (8.6%)

2.34 (1.67–3.29)

<0.0001

0.89 (0.56–1.41)

No

2054/2247 (91.4%)

Ref

–

Ref

0.61
–

Praxis-induced seizures
Yes

103/1609 (6.4%)

1.76 (1.05–2.95)

No

1506/1609 (93.6%)

Ref

0.034

Yes

325/2042 (16%)

2.23 (1.59–3.13)

<0.0001

1.19 (0.86–1.66)

No

1717/2042 (84.0%)

Ref

–

Ref

–

1.10 (0.61–1.99)
Ref

0.75
–

Epileptiform focality on EEG
0.29
–

(Table 1 continues on next page)
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Predictor

n (%) or median (IQR)

Association with drug
resistance
OR (95% CI)

Association with seizure
recurrence after ASM
withdrawal
p-value

HR (95% CI)

p-value

(Continued from previous page)
Photoparoxysmal response
Yes

485/2266 (21.4%)

1.26 (0.99–1.61)

No

1781/2266 (78.6%)

Ref

0.059
–

1.28 (0.96–1.70)
Ref

0.096
–

Motor seizures during sleep
Yes

266/1563 (17%)

1.71 (1.21–2.41)

No

1297/1563 (83.0%)

Ref

0.0032

Yes

156/915 (17.0%)

2.13 (1.44–3.16)

<0.0001

1.27 (0.82–1.98)

No

759/915 (83.0%)

Ref

–

Ref

–

Age at start of ASM reduction (years)

24 (19–31.75)

–

–

0.96 (0.95–0.98)

<0.0001

Epilepsy duration before remission (years)

8 (3–14)

–

–

0.97 (0.95–0.98)

<0.0001

Seizure-free interval before start of
ASM reduction (years)

3 (2–5)

–

–

0.58 (0.46–0.74)

<0.0001

<10

238/289 (82.7%)

–

–

Ref

–

≥10

51/289 (17.3%)

–

0.79 (0.54–1.17)
Ref

0.25
–

Catamenial epilepsya
0.28

Number of GTCS before remission
1.03 (0.69–1.53)

0.90

EEG abnormality before reduction of ASM
Yes

67/221 (30.0%)

No

154/221 (70.0%)

Number of ASMs used at start of reduction

1 (1–1)

–

–

0.93 (0.65–1.34)
Ref

–

–

1.36 (1.01–1.82)

0.70
–
0.045

The ﬁrst column notes the prevalence (%) for categorical variables or the median (IQR) for numerical variables. Missing data differs per variable, and proportions are
calculated based on non-missing data. Odds ratios (OR) are computed for the association with drug resistance and hazard ratios (HR) are computed to assess associations
with seizure recurrence. Positive HR or OR values for numerical variables represent increased risk associated with a higher value. The last six variables are speciﬁc for subjects
that have attempted ASM withdrawal thus we did not calculate associations with drug resistance. aCatamenial epilepsy is a female-speciﬁc risk factor. Thus, we have
calculated the proportion as a fraction of female subjects. ASM: anti-seizure medication.

Table 1: Univariate predictors of drug resistance and seizure recurrence after ASM withdrawal.

C-statistic = 0⋅68; split 2: n = 121, C-statistic = 0⋅74; split
3: n = 128, C-statistic = 0⋅70), with an average C-statistic
of 0⋅70 (95%CI 0⋅68–0⋅73). Plotting observed against
predicted probabilities showed good calibration
(Fig. 4B). As an example, only 44% (95%CI 33–53%) of
people older than 30 years at withdrawal had a recurrence of seizures within two years, compared to 68%
(95%CI 61–73%) of those less than 30 years old
(Supplementary Fig. S5). Assessment of recurrence of
GTCS after ASM withdrawal revealed one additional
risk factor: people who had more than ten GTCS before
remission of seizures (Supplementary Table S16), but
the external predictive value for recurrence of GTCS was
poor (split 1: n = 94, C-statistic = 0⋅64; split 2: n = 94, Cstatistic = 0⋅56; split 3: n = 93, C-statistic = 0⋅61), with an
average C-statistic of 0⋅61 (95%CI 0⋅58–0⋅63).

Discussion
We collected IPD from a large group of people, enabling
the creation of prediction models for individual assessment of drug resistance (n = 2518) and seizure recurrence risk after withdrawal of ASM treatment (n = 368)
in JME. We validated the prediction models and found

8

good calibration. Three-quarters of people who attempted to withdraw ASMs experienced a seizure recurrence
within ﬁve years, for which we found three predictors. A
third of people with JME were drug-resistant, for which
we found nine independent predictors.
We conﬁrmed multiple previously found risk factors
of drug resistance.4,10,45,46 Similar to a previous study
investigating sex-speciﬁc risk factors, we found catamenial epilepsy and absence seizures strongly associated with drug-resistant JME.46 To maximise statistical
power for our prediction model, we did not perform sexstratiﬁed analyses. Therefore, we cannot conﬁrm earlier
reported female-speciﬁc risk factors of drug-resistant
JME.46 Some of these predictors were correlated, and
we included all possible predictors in a sufﬁciently
powered single model. We based our multivariable
prediction model on routinely available variables for the
model to be freely used in clinical practice. Prediction of
a relatively high risk of drug resistance could have implications for counselling and treatment guidance. For
example, a Caucasian woman with catamenial epilepsy,
three seizure types and psychiatric comorbidities has a
high risk of drug resistance. Early referral to a specialised epilepsy clinic should then be considered.
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Fig. 2: (A) Nomogram for prediction of drug-resistant JME. For example, a Caucasian (18 points) girl with a history of febrile seizures (9), who
never had a status epilepticus, who has a psychiatric comorbidity (12.5), no family history of epilepsy (0), three seizure types (19.5), catamenial
epilepsy (13), focal epileptiform activity on EEG (17), no history of childhood absence epilepsy (CAE; 0), has a total 89 points, corresponding to a
90% risk of drug resistance. (B) Calibration plot comparing observed and predicted probabilities, which should ideally follow the diagonal line.

Valproate may be regarded as an option at childbearing
age, but only after careful consideration of the superior
efﬁcacy versus teratogenicity.47 When considering to
start add-on therapy, the attending physician should
base the choice of add-on ASM on the predominant
seizure type.48
We identiﬁed two predictors not previously associated with drug-resistant JME: family history of epilepsy
as a risk factor, and Asian ethnicity was protective
compared to Caucasians. The most likely explanation for
this association is that both predictors are proxies of the
presumed population-speciﬁc genetic basis of JME.49
Alternatively, there might be differences in underreporting seizures relating to cultural and ethnic differences, social stigma, or driving licence regulations.50,51 JME, like other genetic generalised epilepsy
syndromes, is highly polygenic with several thousand
common genetic variants explaining 62% of JME liability, much of which is shared between epilepsy subtypes.49,52 A family history of disease is associated with
an increased polygenic disease burden,53 which might
result in a more severe phenotype with increased risk of
drug resistance.
We found three predictors of seizure recurrence after
ASM withdrawal. There are several predictors of seizure
recurrence in the broader epilepsy population,11 but it is
unknown whether this could be generalised to speciﬁc
syndromes such as JME. We found that only one out of
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eight previously identiﬁed risk factors for seizure
recurrence was predictive in JME. Interestingly, the
strongest predictor in JME, age at ASM withdrawal, has
an opposite direction of effect than in the broader epilepsy population11: older age at withdrawal reduces the
risk of seizure recurrence in JME. In contrast, it increases seizure recurrence risk in a large population of
other epilepsy forms.11 These ﬁndings underscore the
beneﬁt of assessing a speciﬁc epilepsy syndrome instead
of pooling heterogeneous epilepsy subtypes. We found
that two-thirds of people with JME had a recurrence of
seizures within ﬁve years, much higher than for other
types of epilepsy.11 This recurrence risk aligns with the
common perception that people with JME require lifelong treatment. A subset of people, particularly older
people using one ASM with prolonged seizure freedom,
may have a good chance of remaining seizure-free. This
is in line with the ﬁnding that myoclonic seizures often
cease in the fourth decade.26
Our results showed a higher AUC for drug resistance prediction than seizure freedom prediction in the
last one, two, and ﬁve years. The higher AUC suggests
that the formal deﬁnition of drug resistance as deﬁned
by the ILAE,16 which considers the pre-treatment seizure
interval and the number and appropriateness of each
drug trial, is a more robust outcome measure than
seizure freedom alone. We did not achieve excellent
predictive accuracy, despite the large sample size and
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Fig. 3: Survival curve for seizure-freedom after initiation of ASM withdrawal. Freedom of any seizure after withdrawal (blue) and freedom of
generalised tonic-clonic seizures (GTCS; red) after withdrawal are displayed, with the 95% conﬁdence interval in shaded colours. The X-axis
represents the years after start of withdrawal. The number of individuals at risk is displayed below risk for each time point.

the checking of various independent predictors. One
explanation could be that drug response may change
over time, whereas the predictors remain stable
throughout life.54 Indeed, repeated remissions and relapses are common in epilepsy (although not explicitly
assessed in JME-only cohorts),55 and some people
resistant to the ﬁrst two ASM regimens become seizurefree upon a third or later regimen.56,57 Conversely, twothirds of people with drug resistance had a prior
episode of remission longer than one year.58 The ILAE
deﬁnition of drug resistance outperforms previous definitions but there remains a substantial inter- and intraobserver variability.59
We found a higher AUC for predicting seizure
freedom and recurrence of seizures after ASM withdrawal when assessing any seizure type compared to the
analyses conﬁned to GTCS. Analyses on GTCS may lack
statistical power. Alternatively, freedom of GTCS might
be inherently more challenging to predict since GTCS
often occur less frequently than myoclonic or absence
seizures. For example, assessing GTCS freedom in the
last year of follow-up might be an unreliable measure
for someone only having GTCS every other year. Hence,
we would advocate using the ILAE deﬁnition of drug
resistance, which considers all seizure types and pretreatment seizure intervals.
Our study has limitations. The included cohorts were
primarily obtained from tertiary care centres, potentially
limiting the generalisability of our prediction model to
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primary and secondary care. Potential selection bias and
selective loss to follow-up of drug-responsive people
could further reduce the representativeness of our
dataset. We provided a standardised data entry sheet,
but signiﬁcant intra- and inter-observer variability likely
remain. We found considerable heterogeneity between
cohorts. Potential sources of heterogeneity include differences in demography, study ascertainment, countryspeciﬁc healthcare organisation and accessibility. In
particular, differences in ethnicity between studies
could explain part of the heterogeneity in the proportion
of drug resistance, and age differences might explain
heterogeneity in seizure recurrence rate after withdrawal. We mitigated the inﬂuence of between-study
heterogeneity by using random-effect statistical
models, although heterogeneity might have still limited
the predictive performance of our models. As most
studies were several years old, collecting all potential
predictors for each individuals was impossible. We
mitigated this by performing multiple imputations of
missing data, reducing bias and increasing precision.60
We included only readily available clinical predictors.
It is possible that the predictive performance could be
improved if other variables such as genetic diagnostic
investigations, advanced EEG analysis, and functional
MRI measures were included. Only six ethnic Asians
were included in studies outside of Asia, and no Caucasians were included in Asian studies. Therefore, we
were unable to perform stratiﬁed analyses on ethnicity
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Fig. 4: (A) Nomogram for predicting recurrence of any seizure after ASM withdrawal in people with JME. For example, someone with JME who is
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by location JME may be associated with elevated
impulsivity, potentially due to disruption of corticostriatal and thalamocortical networks. This impulsivity
may lead to challenging lifestyles and issues in treatment adherence.61 We attempted to mitigate the inﬂuence of lifestyle and treatment adherence by excluding
people with pseudo-resistance. We could not collect data
on trait impulsivity, so we cannot assess its potential
association with drug resistance. Lastly, the small proportion of individuals that attempted to withdraw treatment limited our analyses on predictors of seizure
recurrence. We were unable to ﬁnd an individually large
enough cohort to perform external validation. However,
our internal-external cross-validations performed by
creating three splits of the 18 cohorts showed robust
external predictive performance of our models,21,22 suggesting that the predictors are similar across different
populations. It is essential to consider these limitations
in the context of the evidence before this study.
Knowledge on JME prognosis and risk factors of drug
resistance is currently based on single-centre cohort
studies without validation, ASM withdrawal is rarely
attempted, and there are currently no known predictors
to guide a safe attempt. Despite some unavoidable
limitations, a meta-analysis of IPD represents the best
available evidence at this moment.62
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In conclusion, we assessed whether we could predict
the likelihood that an individual with JME will become
drug-resistant or has a seizure recurrence after ASM
withdrawal. After validating these predictions, we
created nomograms and developed publicly accessible
web-based tools to help estimate individualised risks
(http://epilepsypredictiontools.info/). We expect that the
models will aid in improving and personalising the
treatment and counselling of people with JME.
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